CACNA1C and amelogenesis imperfecta type 1G: To explore the underlying pathogenic role of sex and the possible therapy for the ERS with CACNA1C-Q1916R, HEK293T cells exogenously expressing the LTCC were treated with the principal male sex hormone, testosterone, or the non-selective β-adrenoceptor agonist, isoproterenol.